90 related articles for article (PubMed ID: 22452518)
1. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
Li WW; Wang XY; Zheng RL; Yan HX; Cao ZX; Zhong L; Wang ZR; Ji P; Yang LL; Wang LJ; Xu Y; Liu JJ; Yang J; Zhang CH; Ma S; Feng S; Sun QZ; Wei YQ; Yang SY
J Med Chem; 2012 Apr; 55(8):3852-66. PubMed ID: 22452518
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
3. Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
Eriksson A; Höglund M; Lindhagen E; Aleskog A; Hassan SB; Ekholm C; Fhölenhag K; Jensen AJ; Löthgren A; Scobie M; Larsson R; Parrow V
Biochem Pharmacol; 2010 Nov; 80(10):1507-16. PubMed ID: 20705060
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.
Lin XD; Yang HW; Ma S; Li WW; Zhang CH; Wang WJ; Xiang R; Li LL; Yang SY
Bioorg Med Chem Lett; 2015 Oct; 25(20):4534-8. PubMed ID: 26342867
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
[TBL] [Abstract][Full Text] [Related]
6. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
[TBL] [Abstract][Full Text] [Related]
7. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
[TBL] [Abstract][Full Text] [Related]
10. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
11. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
Wang C; Lu J; Wang Y; Bai S; Wang Y; Wang L; Sheng G
J Biochem Mol Toxicol; 2012 Jan; 26(1):35-43. PubMed ID: 21928377
[TBL] [Abstract][Full Text] [Related]
13. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
[TBL] [Abstract][Full Text] [Related]
14. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
15. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
16. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
17. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
18. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
[TBL] [Abstract][Full Text] [Related]
19. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
20. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
